Results 51 to 60 of about 6,753 (182)

Case report: Bilateral simple Syndactyly in a toddler with maternal exposure to cabergoline

Clinical Case Reports, 2022
Cabergoline is routinely prescribed in the management of prolactin excreting adenomas and is associated with low risk of congenital malformations and teratogenicity.
Shima Afshar, Mohammad Abbasinazari, Behnam Darvishi, Shadi Ziaie, Hadi Esmaily   +4 more
doaj   +1 more source

Development of a health‐related quality‐of‐life assessment tool for equines with pituitary pars intermedia dysfunction

Equine Veterinary Journal, Volume 58, Issue 1, Page 190-202, January 2026.
Abstract Background Clinical signs of pituitary pars intermedia dysfunction (PPID) are frequently mistaken for ‘normal’ ageing and may not be optimally assessed. Objective quality of life (QoL) assessment could improve clinical decision‐making. Objectives To develop an owner‐reported health‐related quality‐of‐life (HRQoL) assessment tool for equines ...
Aline Bouquet, Christine Nicol, Edward J. Knowles, Imogen Schofield, Nicola J. Menzies‐Gow   +4 more
wiley   +1 more source

FRI322 Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma [PDF]

, 2023
Snigdha Reddy Bendaram, Vitaly Kantorovich   +1 more
openalex   +1 more source

Management of Known Cushing’s Disease in a Nonsurgical Candidate Secondary to a History of Hemorrhagic Stroke Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Cushing’s disease can present with hyperglycemia, hypertension, electrolyte abnormalities, headaches, confusion, gastrointestinal (GI) bleeds, and more. Macroadenomas of the pituitary causing cortisol excess can complicate these cases of patients with a recent hemorrhagic stroke with the medical complexities found within both disease ...
Kyle Distler, Jean Ramos Cardona, Suzanne Martinez, Kalyani Sen   +3 more
wiley   +1 more source

Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial.

PLoS ONE
BackgroundBeneficial effects of dopamine agonist treatment on migraine have been reported but remain to be properly tested. The aim of this study was to examine the effect of cabergoline as preventive treatment for migraine.MethodsIn a double-blind ...
Astrid Johannesson Hjelholt, Flemming Winther Bach, Helge Kasch, Henrik Støvring, Troels Staehelin Jensen, Jens Otto Lunde Jørgensen   +5 more
doaj   +1 more source

Cabergoline-induced mania in a patient of pituitary microadenoma

Indian Journal of Psychological Medicine, 2017
Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj   +1 more source

The Methotrexate Dilemma: Worsening Ovarian Hyperstimulation Syndrome Due to Suspected Ectopic Pregnancy

Case Reports in Obstetrics and Gynecology, Volume 2026, Issue 1, 2026.
Introduction Ovarian hyperstimulation syndrome (OHSS) is typically caused by excessive ovarian stimulation during an in vitro fertilization protocol. Most cases of OHSS are early‐onset, mainly occurring after human chorionic gonadotropic (hCG) trigger, while late‐onset OHSS occurs with positive pregnancy. Very few cases of OHSS occurring due to ectopic
Marita Saliba, Bassem Skaff, Dana Haidar, Barbara Jreij, Toufic I. Nakad, Hannah Wesley   +5 more
wiley   +1 more source

Growth hormone deficiency, secondary hypothyroidism, and empty sella following treatment of childhood macroprolactinoma

Indian Journal of Endocrinology and Metabolism, 2013
Macroprolactinoma are rare in childhood, especially in the first decade. A 9-year-old girl presented with headache, vomiting, and decreased vision for 8 months. A diagnosis of macroprolactinoma was made following documentation of elevated serum prolactin
Chitra Selvan, Deep Dutta, Sujoy Ghosh, Satinath Mukhopadhyay, Subhankar Chowdhury   +4 more
doaj   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, Volume 27, Issue 12, Page 2671-2690, December 2025.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source

Clinical profile and early therapeutic response to cabergoline of patients with hyperprolactinemia in a cameroonian population

The Pan African Medical Journal, 2020
Hyperprolactinemia is responsible for 20 to 25% of consultations of secondary amenorrhea and 17% for female infertility. Dopamine agonists are the gold standard treatment of hyperprolactinemia.
Martine Claude Etoa Etoga, Eugène Sobngwi, Pelagie Ngoune, Emmanuella Doh, Francine Mendane Mekobe, Noel Mbango-Ekouta, Mesmin Dehayem, Pascal Foumane, Jean Claude Mbanya   +8 more
doaj   +1 more source